RESEARCH ARTICLE


Technology Development Through Pooling ARV Drug Patents: A Vision from China



Li Liu1, Hongzhou Lu1, 2, *
1 Department of Infectious Disease, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai, 201508, China
2 Department of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, 00040, China


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 730
Abstract HTML Views: 521
PDF Downloads: 206
Total Views/Downloads: 1457
Unique Statistics:

Full-Text HTML Views: 384
Abstract HTML Views: 223
PDF Downloads: 141
Total Views/Downloads: 748



© Liu and Lu; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Infectious Disease, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai, China; Tel: 0086-21-57248758; E-mail: luhongzhou@fudan.edu.cn


Abstract

Unaffordable prices still bar the end-users in China from accessing ARV drugs. Patent protection of ARV drugs has dramatically limited the availability of these lifesaving drugs to AIDS patients in China.

The way Chinese government can go to breakthrough the ARV drug patents are suggested as:

-  Make more generic drugs available through compulsory licensing, impartment from other countries or building ARVs plants by partnerships between governments or generic drug companies.

-  Do a thorough and detailed research on the patent application of ARV drugs to find out the loophole.

-  Try patent pool to make AIDS medicines more affordable and appropriate for patients.